Louisiana § 40:1125.41 Annual review of Medicaid coverage for sickle cell disease

Louisiana Statutes

§ 40:1125.41 — Annual review of Medicaid coverage for sickle cell disease

Louisiana § 40:1125.41

Title 40Public Health and Safety

This text of Louisiana § 40:1125.41 (Annual review of Medicaid coverage for sickle cell disease) is published on Counsel Stack Legal Research, covering Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

La. Stat. Ann. § 40:1125.41 (2026).

Text

§1125.41. Annual review of Medicaid coverage for sickle cell disease

A.The Louisiana Department of Health shall conduct an annual review of all medications and forms of treatment for sickle cell disease and services for enrollees with a diagnosis of sickle cell disease that are eligible for coverage under the Louisiana Medicaid program. The department shall determine if the available covered medications, treatments, and services are adequate to meet the needs of enrollees with a diagnosis of sickle cell disease and whether the department should seek to add additional medications, treatments, or services.

B.When conducting the annual review required by Subsection A of this Section, the Louisiana Department of Health shall solicit and consider input from the general public with specific em

Free access — add to your briefcase to read the full text and ask questions with AI

§1125.41. Annual review of Medicaid coverage for sickle cell disease
A. The Louisiana Department of Health shall conduct an annual review of all
medications and forms of treatment for sickle cell disease and services for enrollees with a
diagnosis of sickle cell disease that are eligible for coverage under the Louisiana Medicaid
program. The department shall determine if the available covered medications, treatments,
and services are adequate to meet the needs of enrollees with a diagnosis of sickle cell
disease and whether the department should seek to add additional medications, treatments,
or services.
B. When conducting the annual review required by Subsection A of this Section, the
Louisiana Department of Health shall solicit and consider input from the general public with
specific emphasis on attempting to receive input from persons or groups with knowledge and
experience in the area of sickle cell disease treatment.
C. On or before January 15, 2023, and on or before January fifteenth each year
thereafter, the Louisiana Department of Health shall submit a report to the Senate Committee
on Finance, the House Committee on Appropriations, and the Senate and House committees
on health and welfare that details the department's findings from the annual review required
by this Section, as well as any recommendations to the legislature based upon those findings.
The department shall publish the annual report required by this Subsection on its website in
a manner accessible by the general public.